Methods for reducing CD36 expression

Patent metadata

Field	Value
Publication number	US-9150614-B2
Application number	US-201314075686-A
Country	US
Kind code	B2
Filing date	Nov 8, 2013
Priority date	Sep 16, 2005
Publication date	Oct 6, 2015
Grant date	Oct 6, 2015

Abstract

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3 p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.

First claim

What is claimed is:

1. A method for treating diabetic retinopathy in a subject in need thereof comprising administering to the subject an effective amount of an aromatic-cationic peptide having the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or Phe-D-Arg-Phe-Lys-NH 2 or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the peptide has the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .

3. The method of claim 1 , wherein the peptide has the formula Phe-D-Arg-Phe-Lys-NH 2 .

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intramuscularly or transdermally.

6. The method of claim 1 , wherein the method reduces macrophage infiltration in the subject.

7. The method of claim 1 , wherein the method reduces microvascular endothelial cell dysfunction in the subject.

Assignees

• Szeto Hazel H
• Liu Shaoyl
• Cho Sunghee
• Cornell Res Foundation Inc

Inventors

• Szeto Hazel H
• Liu Shaoyl
• Cho Sunghee

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title